Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention.
David Tak Wai LuiC H WongA IpAndrew Kei-Yan NgPublished in: Journal of endocrinological investigation (2023)
Among adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery bypass grafting
- coronary artery disease
- healthcare
- public health
- bone mineral density
- atrial fibrillation
- soft tissue
- health information
- metal organic framework
- hip fracture